781TiP AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors.
Saved in:
| Title: | 781TiP AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors. |
|---|---|
| Authors: | Italiano, A.1 (AUTHOR), Coutzac Bergouignan, C.2 (AUTHOR), Pasquier, D.3 (AUTHOR), Rochigneux, P.4 (AUTHOR), Sablin, M.P.5 (AUTHOR), Gomez-Roca, C.A.6 (AUTHOR), Ghiringhelli, F.7 (AUTHOR), Metges, J-P.8 (AUTHOR), Toulmonde, M.9 (AUTHOR), Cousin, S.10 (AUTHOR), Pernot, S.11 (AUTHOR), Auzanneau, C.12 (AUTHOR), Lortal, B.13 (AUTHOR), Kind, M.14 (AUTHOR), Sargos, P.15 (AUTHOR), Batard, S.16 (AUTHOR), Petit, A.16 (AUTHOR), Gillon, P.16 (AUTHOR), Albert, S.17 (AUTHOR), Pulido, M.17 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS898-S898. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.907 |
